AS eye drops improve ocular surface dryness and decrease epithelial damage

Article

Autologous serum (AS) eye drops on the ocular surface of patients with bilateral severe dry eye improved not only ocular surface dryness, but decreased damage of the epithelium as well, as measured by clinical, laboratory, and subjective criteria, according to results from a study recently published in Current Eye Research

Autologous serum (AS) eye drops on the ocular surface of patients with bilateral severe dry eye improved not only ocular surface dryness, but decreased damage of the epithelium as well, as measured by clinical, laboratory, and subjective criteria, according to results from a study recently published in Current Eye Research.

Researchers from Charles University and the European Eye Clinic Lexum in Prague included 17 patients with severe dry eye in this 3-month prospective study. Autologous serum eye drops were applied 12 times daily (maximum) in addition to regular therapy. Dry eye status was evaluated using visual acuity, Schirmer testing, tear film breakup time, vital staining, tear film debris, and meniscus tests, as well as with conjunctival impression cytology and subjective patient assessment.

Significant improvements were seen with the application of autologous serum eye drops in the Schirmer test (P P P P

In addition, significant decreases were seen in the number of apoptotic, HLA-DR-positive and snake-like chromatin cells on the ocular surface (P

Researchers also noted that while the patients’ subjective point of view of the positive effects of treatment decreased over time, they persisted up to 3 months after therapy had been completed.

To view a copy of the abstract of this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.